Revvity, Inc. (NYSE: RVTY) announced the launch of pHSense™ reagents, a powerful new technology designed to advance internalization studies in drug discovery. The innovative reagents are specifically designed for high-throughput, plate-based workflows and target researchers studying G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs).
Advanced Detection Technology
The pHSense reagents combine a pH-sensitive dye with a time-resolved fluorescence (TRF) readout to deliver robust kinetics of internalization and high signal-to-background ratios, even at low endogenous receptor expression levels. Developed for use with standard plate readers, the reagents are fully compatible with Revvity's multimode detection platforms.
"pHSense reagents fill a critical gap in internalization assay technologies, directed towards enabling researchers to gain faster, more reliable insights using more physiologically relevant conditions," said Craig Monell, senior vice president, reagents at Revvity.
Streamlined Drug Discovery Workflows
The technology offers a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. By significantly enhancing detection capability while simplifying integration into existing drug discovery workflows, pHSense reagents enable more efficient screening and characterization of promising therapeutic candidates.
This enhanced efficiency can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation.
Addressing Market Needs
With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design specifically addresses major limitations of current offerings, including low throughput and suboptimal signal-to-noise ratios.
Revvity reinforces its commitment to advancing drug discovery through innovative tools focused on improving data quality, throughput, and reproducibility with this launch. The company, which reported 2024 revenue of more than $2.7 billion with approximately 11,000 employees, serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments in more than 160 countries.
